<DOC>
	<DOCNO>NCT01798251</DOCNO>
	<brief_summary>To confirm efficacy safety XELOX capecitabine maintenance treatment elderly advance gastric cancer ( AGC ) compare XELOX regimen .</brief_summary>
	<brief_title>XELOX With Capecitabine Maintenance XELOX Elderly Metastatic Adenocarcinoma Stomach</brief_title>
	<detailed_description>To investigate whether XELOX capecitabine maintenance treatment 1st line treatment elderly advance gastric cancer effective safe XELOX regimen .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Ages Eligible Study : 65 Years old Genders Eligible Study : Both The Eastern Cooperative Oncology Group ( ECOG ) status â‰¤ 2 Histologically confirm gastric adenocarcinoma ( include LAUREN type ) . Measurable disease ( accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria 1.1 ) . chemotherapy naive recurrence metastasis . Previous neoadjuvant adjuvant treatment gastric cancer , applicable , 6 month . Hb &gt; 90g/L , neutrophil count &gt; = 1.5*10^9/L , platelet &gt; = 100*10^9/L , alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &lt; = 2.5 time upper limit nominal ( ULN ) , alkaline phosphatase ( ALP ) &lt; = 2.5 time ULN , total bilirubin ( TBIL ) &lt; 1.5 time ULN , serum albumin level &gt; = 30g/L , serum creatinine &lt; 1 time ULN . No serious concomitant disease could lead death within 5 year . At least 5 year last Biological/Immunotherapy/Hormone treatment Malignancy exclude gastric cancer . Able accept oral medication Compliance protocol Had receive cytotoxic chemotherapy , radiotherapy immunotherapy gastric cancer , exclude Corticosteroids . Other previous malignancy within 5 year , except curative skin cancer carcinoma situ uterine cervix . Uncontrolled epilepsy , central nervous system disorder , history mental disorder . clinically significant ( i.e . active ) cardiac disease e.g . symptomatic coronary artery disease , New York Heart Association ( NYHA ) II serious congestive heart failure severe require medication intervention arrhythmia , history myocardial infarction within last 12 month . Upper gastrointestinal obstruction physiological dysfunction suffer malabsorption syndrome , could affect absorption capecitabine . Organ transplantation require immunosuppressive treatment . Severe uncontrolled recurrent infection , Other serious uncontrolled concomitant disease . Moderate severe renal impairment ( creatinine clearance ( CCr ) = &lt; 50 ml/min ) , serum creatinine &gt; ULN . Known enzyme deficiency dihydropyrimidine dehydrogenase ( DPD ) . Allergy Oxaliplatin study medication ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Elderly Gastric Cancer</keyword>
	<keyword>Capecitabine Maintenance</keyword>
</DOC>